Meta-analysis compares response rates of CTCL targeted and immune therapies

A systematic review and meta-analysis of 41 studies (1660 patients) evaluated targeted and immune-based monotherapies in cutaneous T-cell lymphoma, including mycosis fungoides and Sézary syndrome. The analysis reported pooled overall response rates ranging from 34% with pembrolizumab to 69% with brentuximab vedotin, with duration of response of 4.7 to 9.4 months and progression-free survival of 14.4 to 23.3 months across therapies; grade 3 or greater adverse event rates ranged from 15% with mogamulizumab to 26% with denileukin diftitox. The authors state that therapeutic activity varied by disease subtype and that response rates, durability, and toxicity differed across treatment cohorts.

Most relevant for: Patients with advanced mycosis fungoides or Sézary syndrome being considered for targeted or immune-based monotherapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.